세계의 생명과학 분석 시장 : 유형별, 구성요소별, 용도별, 최종사용자별, 지역별 - 예측(-2029년)

Life Science Analytics Market by Type (Descriptive, Prescriptive, Predictive), Service (Analytics), Application (Drug Discovery, Trials, RWE, Access, Sales & marketing, Drug Safety), End User (Pharma, Medical Device), & Region - Global Forecast to 2029

US $ 4,950 ￦ 7,024,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,437,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,565,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,191,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 생명과학 분석 시장 규모는 2024년 356억 9,000만 달러에서 2029년에는 619억 4,000만 달러에 달할 것으로 예상되며, 예측 기간 동안 11.7%의 CAGR을 기록할 것으로 예상됩니다.

이 시장은 생명과학 분야의 빅데이터의 이질성과 복잡성, 연구개발, 상업화(시장 진입, 가격 책정, 판매 및 마케팅 등), 안전 등 산업 전반의 다양한 용도에서 기술적으로 진보된 분석 솔루션에 대한 수요가 급증함에 따라 성장할 것으로 예상됩니다. 또한, 생명과학 및 헬스케어 산업 전반에 걸쳐 데이터 표준화를 개선할 필요성이 대두되면서 시장이 성장하고 있습니다. 다만, IT 인프라의 미비, 신흥국의 분석 솔루션 도입에 대한 거부감 등이 시장 성장의 걸림돌로 작용할 것으로 예상됩니다.

조사 범위
조사 대상 연도	2022-2029년
기준 연도	2023년
예측 기간	2024-2029년
검토 단위	100만/10억(달러)
부문별	유형별, 구성요소별, 용도별, 최종사용자별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

생명과학 분석 소프트웨어 부문은 온프레미스, 클라우드 기반, SaaS로 세분화되며, 2023년에는 SaaS(Software-as-a-Service) 부문이 예측 기간 동안 가장 높은 성장률을 기록할 것으로 예측됩니다. SaaS 부문의 성장은 다양한 클라우드 사일로의 데이터 통합, 원격지에서의 무제한 사용자 액세스, 낮은 유지보수 비용, 높은 보안, 프라이버시, 쉬운 접근성, 하드웨어에 대한 선투자 불필요, 높은 용량 유연성, 최적화된 리소스 활용 등 다양한 장점으로 인해 SaaS 부문의 성장이 예상됩니다. 리소스 활용 등 이 모델이 제공하는 많은 장점에 기인합니다. 또한, SaaS 모델이 제공하는 다양한 애플리케이션은 회계, 성능 모니터링, 웹 메일 및 인스턴트 메신저를 통한 커뮤니케이션 등 다양한 분야에서 활용되고 있으며, 이는 이 부문의 성장에 더욱 기여하고 있습니다.

제약 및 생명공학 기업, 의료기기 제조업체, 연구기관, CRO, CMO, 독립 계약자 등 아웃소싱 생명과학 조직이 생명과학 분석 시장의 최종사용자 부문을 구성하고 있으며, 2023년에는 제약 및 생명공학 기업이 최종사용자별 생명과학 분석 시장에서 가장 큰 비중을 차지했습니다. 최종사용자별 생명과학 분석 시장에서 큰 비중을 차지할 것으로 예상됩니다. 또한, 이 부문은 예측 기간 동안 가장 큰 성장을 기록할 것으로 예상됩니다. 제약 및 바이오테크 기업의 R&D 비용 증가, R&D 프로세스, 의약품 판매 및 마케팅에 대한 분석 활용 증가, 약물감시에서 분석의 중요성 증가, 데이터 기반 인사이트 기반의 신약 개발 가속화 등이 이 부문의 높은 성장세를 뒷받침하고 있습니다. 데이터 기반 인사이트를 통한 신약개발 가속화, 임상시험 최적화, 규제 준수 강화의 필요성 등이 있습니다. 또한, 맞춤형 의료와 정밀 치료의 발전, AI와 머신러닝의 통합은 제약 및 생명공학 산업에서 애널리틱스의 가치를 더욱 높이고 있습니다.

이 보고서는 세계 생명과학 분석 시장을 조사하여 유형별, 구성요소별, 용도별, 최종사용자별, 지역별 동향, 시장 진입 기업 개요 등을 정리한 보고서입니다.

목차

제1장 소개

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 소개
• 시장 역학
• 업계 동향
• 기술 분석
• 생태계 분석
• 밸류체인 분석
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 사례 연구 분석
• 규제 상황
• 가격 분석
• 2024-2025년의 주요 회의와 이벤트
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 특허 분석
• 최종사용자 분석
• 생명과학 분석 비즈니스 모델
• 투자와 자금 조달 시나리오
• AI/생성형 AI가 생명과학 분석 시장에 미치는 영향

제6장 생명과학 분석 시장(유형별)

• 소개
• 기술적 분석
• 예측적 분석
• 처방적 분석

제7장 생명과학 분석 시장(구성요소별)

• 소개
• 서비스
• 소프트웨어

제8장 생명과학 분석 시장(용도별)

• 소개
• 연구개발
• 상업 분석
• 규제 준수
• 제조와 공급망 최적화
• 안전성

제9장 생명과학 분석 시장(최종사용자별)

• 소개
• 제약·바이오테크놀러지 기업
• 의료기기 제조업체
• 연구 센터
• 아웃소싱 생명과학 조직

제10장 생명과학 분석 시장(지역별)

• 소개
• 북미
  • 북미 : 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양 : 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 기타
• 라틴아메리카
  • 라틴아메리카 : 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 중동 및 아프리카 : 거시경제 전망
  • GCC 국가
  • 기타

제11장 경쟁 구도

• 개요
• 주요 진출 기업 전략/강점
• 매출 분석
• 시장 점유율 분석
• 기업 평가 매트릭스 : 주요 진출 기업, 2023년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2023년
• 브랜드/소프트웨어 비교 분석
• 평가와 재무 지표
• 경쟁 시나리오

제12장 기업 개요

• 주요 진출 기업
  • ORACLE
  • MERATIVE
  • SAS INSTITUTE INC.
  • ACCENTURE
  • IQVIA INC.
  • COGNIZANT
  • WIPRO
  • VERADIGM LLC
  • OPTUM, INC.
  • MICROSOFT
  • MAXISIT
  • EXLSERVICE HOLDINGS, INC.
  • INOVALON
  • CITIUSTECH INC.
  • SAAMA
  • AXTRIA
  • CLARIVATE
  • THOUGHTSPHERE
  • THOUGHTSPOT INC.
  • SALESFORCE, INC.
• 기타 기업
  • GOOGLE LLC
  • AMAZON WEB SERVICES, INC.
  • VEEVA SYSTEMS
  • ELSEVIER
  • KOMODO HEALTH, INC.

제13장 부록

KSM

영문 목차

영문목차

The global Life science analytics market is projected to reach USD 61.94 billion by 2029 from USD 35.69 billion in 2024, at a CAGR of 11.7% during the forecast period. The market is expected to grow as a result of the heterogenity & complexity of big data in life sciences, surging demand for technologically advanced analytical solutions for various applications across the industry, such as, research & development, commercialization (market access, pricing, sales & marketing, etc), safety, among others. Moreover, the market has experienced growth due to the need for improved data standardization across the life science & healthcare industry. However, insufficient IT infrastructure, and reluctance towards adoption of analytics solutions in emerging economies are some of the factors that are expected to pose a challenge to the market growth.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Million/Billion (USD)
Segments	By Type, Component, Application, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

"Software-as-a-service (SaaS) subsegment, under the life science analytics software segment is expected to register highest growth during the forecast period."

The life science analytics software segment is sub-segmented into on-premise, cloud-based, and software-as-a-service. In 2023, the software-as-a-service (SaaS) segment is expected to register the highest growth during the forecast period. The growth of the SaaS segment is attributed to the ample number of advantages offered by this model, such as the seamless integration of data from various cloud silos, unlimited user access from remote locations, low maintenance costs, high security, privacy, easy accessibility, no upfront capital investment for hardware, and extreme capacity flexibility and optimized resource utilization. Moreover, several applications offered by the SaaS model, spanning areas such as accounting, performance monitoring, and communication through webmail and instant messengers, further contribute to the segment's growth.

"Pharmaceutical & Biotechnology companies is projected to dominate the market in the life science analytics market, by end user during the forecast period."

The pharmaceutical & biotechnology companies, medical device companies, research institutes, and outsourced life science organizations such as CROS, CMOs, independent contractors, etc., make up the end user segments of the life science analytics market. In 2023, the pharmaceutical & biotechnology companies accounted for a significant share of the life science analytics market, by end user. The segment is also expected to register paramount growth during the forecast period. The prominent position & high growth of this segment is due to the increasing R&D expenditure of pharma & biotech companies, the increasing use of analytics for research & development processes, pharma sales and marketing, growing importance of analytics in pharmacovigilance, the need to accelerate drug discovery, optimize clinical trials, and enhance regulatory compliance through data-driven insights. Moreover, the push for personalized medicine and precision therapeutics, The integration of AI and machine learning further strengthens the value of analytics in the pharma & biotech industry.

"Asia Pacific is expected to register highest market growth during the forecast period."

The life science analytics market is bifurcated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific region is expected to register highest growth during the forecast period. The high growth of this region is attributed to the the presence of a large and growing patient population in the region, the increasing need for innovative therapies, the emergence of big data in healthcare, increasing spending on HCIT infrastructure, and the shifting focus of various market players on emerging countries in the region. Government initiatives to promote the adoption of digital & technologically enabled solutions across life science industry, and significant focus on integrating sophisticated technologies across the workflows also contributes to the growth.

The break-down of primary participants is as mentioned below:

• By Company Type - Tier 1: 32%, Tier 2: 44%, and Tier 3: 24%
• By Designation - Directors: 30%, Manager: 34%, and Others: 36%
• By Region - North America: 40%, Europe: 28%, Asia Pacific: 20%, Latin America: 7% and Middle East & Africa: 5%

List of Companies Profiled in the Report

• Oracle (US)
• Merative (formerly IBM) (US)
• SAS Institute (US)
• Accenture (Ireland)
• IQVIA (US)
• Cognizant (US)
• Wipro (India)
• Veradigm (US)
• Optum (US)
• Microsoft (US)
• MaxisIT (US)
• ExlService Holdings (US)
• Inovalon (US)
• CitiusTech (US)
• Saama (US)
• Axtria (US)
• Clarivate (UK)
• ThoughtSphere (US)
• ThoughtSpot (US)
• Salesforce (US)
• Google LLC (US)
• Amazon Web Services, Inc. (US)
• Veeva Systems (US)
• Elsevier (Netherlands)
• Komodo Health, Inc. (US)

Research Coverage:

The report analyzes the Life science analytics market and aims to estimate the market size and future growth potential of various market segments, based on type, component, applicarion, end user, and region. The report also analyses factors (such as drivers, opportunities and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total life science analytics market. The report forecasts the revenue of the market segments with respect to five major regions. The report also provides a competitive analysis of the key players operating in this market, along with their company profiles, product offerings, recent developments, and key market strategies.

Reasons to Buy the Report

This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

• Analysis of key drivers (rising pressure to curb healthcare spending, need for improved data standardization, technological advancements in analytical solutions, heterogeneity and complexity of big data in life sciences, growing adoption of analytical solutions in clinical trials, increasing R&D expenditure in pharmaceutical & biotechnology companies), restraints (high implementation costs of advanced analytical solutions, data privacy concerns), opportunities (growing focus on value-based care, use of analytics in precision & personalized medicine, big data analytics for R&D productivity, growing adoption of cloud-based analytics), challenges (issues associated with data integration, shortage of skilled personnel, reluctance to adopt life science analytics solutions in emerging countries) are factors contributing the growth of the life science analytics market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the life science analytics market.
• Market Development: Comprehensive information on the lucrative emerging markets, type of solution, component, deployment model, industry, and region.
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, investments in the life science analytics market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global life science analytics market such as Oracle (US), Merative (formerly IBM) (US), SAS Institute (US), Accenture (Ireland), IQVIA (US), Cognizant (US), Wipro (India), Veradigm (US), Optum (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 LIMITATIONS
  • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.6.2 SCOPE-RELATED LIMITATIONS
• 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LIFE SCIENCE ANALYTICS MARKET OVERVIEW
• 4.2 LIFE SCIENCE ANALYTICS MARKET, BY REGION
• 4.3 NORTH AMERICA: LIFE SCIENCE ANALYTICS MARKET, BY END USER & REGION
• 4.4 LIFE SCIENCE ANALYTICS MARKET: GEOGRAPHIC SNAPSHOT
• 4.5 LIFE SCIENCE ANALYTICS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising pressure to curb healthcare spending
    • 5.2.1.2 Need for improved data standardization
    • 5.2.1.3 Technological advancements in analytical solutions
    • 5.2.1.4 Heterogeneity and complexity of big data in life sciences
    • 5.2.1.5 Growing adoption of analytical solutions in clinical trials
    • 5.2.1.6 Increasing R&D expenditure in pharmaceutical & biotechnology companies
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High implementation costs of advanced analytical solutions
    • 5.2.2.2 Data privacy concerns
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing focus on value-based care
    • 5.2.3.2 Use of analytics in precision & personalized medicine
    • 5.2.3.3 Big data analytics for R&D productivity
    • 5.2.3.4 Growing adoption of cloud-based analytics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Issues associated with data integration
    • 5.2.4.2 Shortage of skilled personnel
    • 5.2.4.3 Reluctance to adopt life science analytics solutions in emerging countries
• 5.3 INDUSTRY TRENDS
  • 5.3.1 GROWING ADOPTION OF ANALYTICS IN COMMERCIAL OPERATIONS
  • 5.3.2 LEVERAGING DATA & ANALYTICS TO ACCELERATE DRUG DISCOVERY & DEVELOPMENT
  • 5.3.3 FOCUS ON REAL-TIME DATA ANALYTICS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Artificial intelligence and machine learning
    • 5.4.1.2 Big data analytics
    • 5.4.1.3 Quantum computing
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Bioinformatics tools
    • 5.4.2.2 Internet of things
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Blockchain
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 PORTER'S FIVE FORCES ANALYSIS
  • 5.7.1 THREAT OF NEW ENTRANTS
  • 5.7.2 THREAT OF SUBSTITUTES
  • 5.7.3 BARGAINING POWER OF SUPPLIERS
  • 5.7.4 BARGAINING POWER OF BUYERS
  • 5.7.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.8.2 BUYING CRITERIA
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 NOVARTIS USES MULTI-CLOUD DATA ANALYTICS PLATFORM TO OPTIMIZE OPERATIONS AND ACCELERATE INNOVATION
  • 5.9.2 SAS VISUAL ANALYTICS HELPS MAXIMIZE PROFITABILITY THROUGH PRESCRIPTIVE ANALYTICS & DATA VISUALIZATION
  • 5.9.3 STREAMLINING REGULATORY MONITORING AND IMPACT ASSESSMENTS: GEDEON RICHTER'S PARTNERSHIP WITH CLARIVATE
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 NORTH AMERICA
  • 5.10.3 EUROPE
  • 5.10.4 ASIA PACIFIC
  • 5.10.5 MIDDLE EAST & AFRICA
  • 5.10.6 LATIN AMERICA
• 5.11 PRICING ANALYSIS
  • 5.11.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY APPLICATION
  • 5.11.2 AVERAGE SELLING PRICE, BY REGION
• 5.12 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.14 PATENT ANALYSIS
  • 5.14.1 PATENT PUBLICATION TRENDS
  • 5.14.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES
  • 5.14.3 MAJOR PATENTS
• 5.15 END USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 LIFE SCIENCE ANALYTICS BUSINESS MODELS
  • 5.16.1 SUBSCRIPTION-BASED MODEL
  • 5.16.2 SAAS MODEL
  • 5.16.3 PAY-PER-USE/USAGE-BASED MODEL
  • 5.16.4 ENTERPRISE LICENSING
  • 5.16.5 FREEMIUM MODEL
  • 5.16.6 ENTERPRISE LICENSING
  • 5.16.7 CONCURRENT LICENSING
  • 5.16.8 CONSULTING SERVICES MODEL
  • 5.16.9 PARTNERSHIP/REVENUE-SHARING MODEL
  • 5.16.10 HYBRID MODELS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF AI/GENERATIVE AI ON LIFE SCIENCE ANALYTICS MARKET
  • 5.18.1 TOP USE CASES & MARKET POTENTIAL
    • 5.18.1.1 Key use cases
  • 5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
    • 5.18.2.1 Case Study 1: Knowledge Mining for a Global Biopharmaceutical Company
    • 5.18.2.2 Healthcare analytics market
  • 5.18.3 USER READINESS AND IMPACT ASSESSMENT
    • 5.18.3.1 User readiness
      • 5.18.3.1.1 Pharmaceutical & biotechnology companies
      • 5.18.3.1.2 Medical device companies
      • 5.18.3.1.3 Research centers
      • 5.18.3.1.4 Outsourced life science organizations
    • 5.18.3.2 Impact assessment
      • 5.18.3.2.1 User A: Pharmaceutical & biotechnology companies
        • 5.18.3.2.1.1 Implementation
        • 5.18.3.2.1.2 Impact
      • 5.18.3.2.2 User B: Medical device companies
        • 5.18.3.2.2.1 Implementation
        • 5.18.3.2.2.2 Impact
      • 5.18.3.2.3 User C: Research institutes
        • 5.18.3.2.3.1 Implementation
        • 5.18.3.2.3.2 Impact
      • 5.18.3.2.4 User D: Outsourced life science organizations
        • 5.18.3.2.4.1 Implementation
        • 5.18.3.2.4.2 Impact

6 LIFE SCIENCE ANALYTICS MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 DESCRIPTIVE ANALYTICS
  • 6.2.1 ADVANCED VISUAL DATA EXPLORATION AND SUPPORT FOR INNOVATION TO DRIVE DEMAND
• 6.3 PREDICTIVE ANALYTICS
  • 6.3.1 SIMULATION DEVELOPMENT FOR PREDICTING FUTURE TRENDS TO PROPEL MARKET GROWTH
• 6.4 PRESCRIPTIVE ANALYTICS
  • 6.4.1 REAL-TIME ANALYSIS FOR IMPROVED DECISION-MAKING TO SUPPORT MARKET GROWTH

7 LIFE SCIENCE ANALYTICS MARKET, BY COMPONENT

• 7.1 INTRODUCTION
• 7.2 SERVICES
  • 7.2.1 MANAGED SERVICES
    • 7.2.1.1 Analytical services
      • 7.2.1.1.1 Focus on expediting approvals and product launches to drive growth
    • 7.2.1.2 Consulting services
      • 7.2.1.2.1 Support for R&D, process development, and other workflow processes to drive market
  • 7.2.2 PROFESSIONAL SERVICES
    • 7.2.2.1 Training & implementation
      • 7.2.2.1.1 Stringent regulations, increasing competition, and need for skill development to propel demand
    • 7.2.2.2 Maintenance & support services
      • 7.2.2.2.1 Rising complexity of analytical technologies and expanding research needs to support market growth
    • 7.2.2.3 Other professional services
• 7.3 SOFTWARE
  • 7.3.1 ON-PREMISE SOLUTIONS
    • 7.3.1.1 Provision of multivendor architecture and security benefits to drive market
  • 7.3.2 CLOUD-BASED SOLUTIONS
    • 7.3.2.1 Real-time analysis and elimination of purchasing costs for software & hardware to drive adoption
  • 7.3.3 SAAS-BASED SOLUTIONS
    • 7.3.3.1 Increasing adoption of digital solutions and advantages of cloud-based models to drive growth

8 LIFE SCIENCE ANALYTICS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 RESEARCH & DEVELOPMENT
  • 8.2.1 CLINICAL TRIALS
    • 8.2.1.1 Life science analytics market for clinical trials, by type
      • 8.2.1.1.1 Laboratory services
        • 8.2.1.1.1.1 Better accuracy, efficiency, and data interpretation to support demand for lab services
      • 8.2.1.1.2 Patient recruitment services
        • 8.2.1.1.2.1 Need for better candidate identification and enrollment forecasting to propel market growth
      • 8.2.1.1.3 Site identification services
        • 8.2.1.1.3.1 Benefits in locating ideal trial sites and interpreting data to support adoption
      • 8.2.1.1.4 Other clinical trial services
    • 8.2.1.2 Life science analytics market for clinical trials, by phase
      • 8.2.1.2.1 PHASE I
        • 8.2.1.2.1.1 Strong pipeline of pharmaceutical companies to propel market growth
      • 8.2.1.2.2 PHASE II
        • 8.2.1.2.2.1 Extended duration of phase II studies to create growth opportunities for CROs
      • 8.2.1.2.3 PHASE III
        • 8.2.1.2.3.1 Rising trial expenditure to drive demand for cost-effective clinical research services
  • 8.2.2 PRECLINICAL & DRUG DISCOVERY
    • 8.2.2.1 Ability to assist researchers in process innovation and decision support to drive adoption
• 8.3 COMMERCIAL ANALYTICS
  • 8.3.1 SALES & MARKETING SUPPORT
    • 8.3.1.1 Rising analysis of digital marketing effectiveness to drive adoption
  • 8.3.2 MARKET ACCESS
    • 8.3.2.1 Focus on strategic pricing, reimbursement, and policy changes to support market growth
  • 8.3.3 RWE & VALUE EVIDENCE
    • 8.3.3.1 Increased data integration, partnerships, and technological to propel use of RWE
  • 8.3.4 ENGAGEMENT SERVICES
    • 8.3.4.1 Need for better patient engagement, digital advancements, and AI integration to propel market
• 8.4 REGULATORY COMPLIANCE
  • 8.4.1 STRINGENT REQUIREMENTS FOR COMPLIANCE ADHERENCE TO DRIVE ADOPTION
• 8.5 MANUFACTURING & SUPPLY CHAIN OPTIMIZATION
  • 8.5.1 RISING NEED FOR REDUCING LOGISTICS COSTS TO SUPPORT MARKET GROWTH
• 8.6 SAFETY
  • 8.6.1 PHARMACOVIGILANCE
    • 8.6.1.1 Monitoring of drug trials and medication programs to fuel market uptake
  • 8.6.2 MEDICAL DEVICE SAFETY
    • 8.6.2.1 Stringent safety standards, rigorous risk assessments, and robust quality control to drive demand
  • 8.6.3 DIAGNOSTIC VIGILANCE
    • 8.6.3.1 Continuous monitoring, integration of diverse data sources, and ongoing education to enhance accuracy and thoroughness

9 LIFE SCIENCE ANALYTICS MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 RISING NEED FOR INNOVATIVE THERAPIES TO DRIVE ANALYTICS USAGE IN PRODUCT DEVELOPMENT
• 9.3 MEDICAL DEVICE COMPANIES
  • 9.3.1 ADOPTION OF DATA ANALYTICS FOR DEVICE COMMERCIALIZATION TO DRIVE MARKET
• 9.4 RESEARCH CENTERS
  • 9.4.1 NEED FOR ANALYZING LARGE VOLUMES OF DATA TO SUPPORT MARKET GROWTH
• 9.5 OUTSOURCED LIFE SCIENCE ORGANIZATIONS
  • 9.5.1 RISING R&D OUTSOURCING BY LIFE SCIENCE COMPANIES TO DRIVE MARKET

10 LIFE SCIENCE ANALYTICS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 Established economy and increasing R&D expenditure to drive adoption of analytical solutions
  • 10.2.3 CANADA
    • 10.2.3.1 Rising need for data standardization in life sciences to fuel uptake
• 10.3 EUROPE
  • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 10.3.2 GERMANY
    • 10.3.2.1 Growing R&D investments by pharmaceutical & biotechnology companies to drive market
  • 10.3.3 FRANCE
    • 10.3.3.1 Growing government support for adoption of AI & big data analytics to drive market
  • 10.3.4 UK
    • 10.3.4.1 Rising clinical trial activity to drive uptake of life science analytics solutions
  • 10.3.5 ITALY
    • 10.3.5.1 Growing number of drug approvals to drive uptake of analytics solutions
  • 10.3.6 SPAIN
    • 10.3.6.1 Surging government investments focusing on personalized medicine to drive growth
  • 10.3.7 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 10.4.2 JAPAN
    • 10.4.2.1 Growing government support for clinical R&D activities to drive adoption
  • 10.4.3 CHINA
    • 10.4.3.1 Growth in life science industry to support adoption of solutions
  • 10.4.4 INDIA
    • 10.4.4.1 Rising R&D expenditure and drug development to support market growth
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 Brazil to dominate life science analytics market in Latin America
  • 10.5.3 MEXICO
    • 10.5.3.1 Growing prominence of startups and rising R&D activity to propel market
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 10.6.2 GCC COUNTRIES
    • 10.6.2.1 Rising investments, advancements, and developing healthcare infrastructure to drive market
  • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN LIFE SCIENCE ANALYTICS MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Type footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 Component footprint
    • 11.5.5.5 End user footprint
    • 11.5.5.6 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING
• 11.7 BRAND/SOFTWARE COMPARATIVE ANALYSIS
• 11.8 VALUATION & FINANCIAL METRICS
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES & ENHANCEMENTS
  • 11.9.2 DEALS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 ORACLE
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products & services offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Product launches & enhancements
      • 12.1.1.3.2 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses & competitive threats
  • 12.1.2 MERATIVE
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products & services offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Right to win
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses & competitive threats
  • 12.1.3 SAS INSTITUTE INC.
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products & services offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Product launches & enhancements
      • 12.1.3.3.2 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Right to win
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses & competitive threats
  • 12.1.4 ACCENTURE
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product launches & enhancements
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Right to win
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses & competitive threats
  • 12.1.5 IQVIA INC.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products & services offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches & enhancements
      • 12.1.5.3.2 Deals
      • 12.1.5.3.3 Other developments
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Right to win
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses & competitive threats
  • 12.1.6 COGNIZANT
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products & services offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & enhancements
      • 12.1.6.3.2 Deals
  • 12.1.7 WIPRO
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products & services offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 VERADIGM LLC
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products & services offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Deals
  • 12.1.9 OPTUM, INC.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products & services offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Deals
  • 12.1.10 MICROSOFT
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products & services offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product launches & enhancements
      • 12.1.10.3.2 Deals
  • 12.1.11 MAXISIT
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products & services offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches & enhancements
      • 12.1.11.3.2 Deals
  • 12.1.12 EXLSERVICE HOLDINGS, INC.
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products & services offered
    • 12.1.12.3 Recent developments
      • 12.1.12.3.1 Product launches & enhancements
      • 12.1.12.3.2 Deals
  • 12.1.13 INOVALON
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products & services offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches & enhancements
      • 12.1.13.3.2 Deals
  • 12.1.14 CITIUSTECH INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products & services offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches & enhancements
      • 12.1.14.3.2 Deals
      • 12.1.14.3.3 Expansions
  • 12.1.15 SAAMA
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products & services offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Deals
  • 12.1.16 AXTRIA
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products & services offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Product launches & enhancements
      • 12.1.16.3.2 Deals
      • 12.1.16.3.3 Expansions
  • 12.1.17 CLARIVATE
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products & services offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product launches & enhancements
      • 12.1.17.3.2 Deals
  • 12.1.18 THOUGHTSPHERE
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products & services offered
    • 12.1.18.3 Recent developments
      • 12.1.18.3.1 Deals
  • 12.1.19 THOUGHTSPOT INC.
    • 12.1.19.1 Business overview
    • 12.1.19.2 Products & services offered
    • 12.1.19.3 Recent developments
      • 12.1.19.3.1 Deals
      • 12.1.19.3.2 Expansions
  • 12.1.20 SALESFORCE, INC.
    • 12.1.20.1 Business overview
    • 12.1.20.2 Products & services offered
    • 12.1.20.3 Recent developments
      • 12.1.20.3.1 Product launches & enhancements
      • 12.1.20.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 GOOGLE LLC
  • 12.2.2 AMAZON WEB SERVICES, INC.
  • 12.2.3 VEEVA SYSTEMS
  • 12.2.4 ELSEVIER
  • 12.2.5 KOMODO HEALTH, INC.

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS

관련자료